CN106999535B - 用于治疗疾病和病症的NFκB活性的抑制剂 - Google Patents

用于治疗疾病和病症的NFκB活性的抑制剂 Download PDF

Info

Publication number
CN106999535B
CN106999535B CN201580064157.3A CN201580064157A CN106999535B CN 106999535 B CN106999535 B CN 106999535B CN 201580064157 A CN201580064157 A CN 201580064157A CN 106999535 B CN106999535 B CN 106999535B
Authority
CN
China
Prior art keywords
inflammation
administration
group
patient
core sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580064157.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999535A (zh
Inventor
拉金德拉·萨哈伊·巴特纳格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111512016.7A priority Critical patent/CN114432423B/zh
Publication of CN106999535A publication Critical patent/CN106999535A/zh
Application granted granted Critical
Publication of CN106999535B publication Critical patent/CN106999535B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580064157.3A 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂 Active CN106999535B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111512016.7A CN114432423B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NF κB活性的抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111512016.7A Division CN114432423B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NF κB活性的抑制剂

Publications (2)

Publication Number Publication Date
CN106999535A CN106999535A (zh) 2017-08-01
CN106999535B true CN106999535B (zh) 2021-12-21

Family

ID=55582262

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580064157.3A Active CN106999535B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂
CN202111512016.7A Active CN114432423B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NF κB活性的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111512016.7A Active CN114432423B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NF κB活性的抑制剂

Country Status (7)

Country Link
US (5) US10030048B2 (enExample)
EP (1) EP3197474B1 (enExample)
JP (3) JP6851965B2 (enExample)
CN (2) CN106999535B (enExample)
AU (2) AU2015320341B2 (enExample)
CA (1) CA2999711A1 (enExample)
WO (1) WO2016049580A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
US20220133837A1 (en) * 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
EP0487617B1 (en) 1989-08-14 1996-10-02 The Regents Of The University Of California Synthetic peptides that enhance cell binding
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
JP4943848B2 (ja) * 2003-10-07 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｎｉｋに対する抗体、その調製および使用
US20060211075A1 (en) * 2005-03-02 2006-09-21 The Albert Einstein College Of Medicine Of Yeshiva University Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
US8614186B2 (en) * 2009-05-27 2013-12-24 Dana-Farber Cancer Institute, Inc. Inhibition of inflammation using antagonists of MUC1
CA2785038A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
US20220133837A1 (en) 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Also Published As

Publication number Publication date
AU2021221579A1 (en) 2021-09-16
US20260015386A1 (en) 2026-01-15
CN114432423A (zh) 2022-05-06
CN114432423B (zh) 2026-06-26
JP6851965B2 (ja) 2021-03-31
US20240083941A1 (en) 2024-03-14
US20220106359A1 (en) 2022-04-07
WO2016049580A2 (en) 2016-03-31
US11174286B2 (en) 2021-11-16
EP3197474A4 (en) 2018-08-22
EP3197474C0 (en) 2023-06-07
US10030048B2 (en) 2018-07-24
CN106999535A (zh) 2017-08-01
US12325760B2 (en) 2025-06-10
JP7184946B2 (ja) 2022-12-06
CA2999711A1 (en) 2016-03-31
AU2015320341B2 (en) 2021-05-27
JP2018500274A (ja) 2018-01-11
AU2021221579B2 (en) 2025-01-23
JP2023010979A (ja) 2023-01-20
US20180298055A1 (en) 2018-10-18
EP3197474B1 (en) 2023-06-07
US11773135B2 (en) 2023-10-03
EP3197474A2 (en) 2017-08-02
US20170051012A1 (en) 2017-02-23
WO2016049580A3 (en) 2016-05-19
AU2015320341A1 (en) 2017-05-04
JP2021091728A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
US12325760B2 (en) Inhibitors of NF kappa-B activity for treatment of diseases and disorders
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
US10729636B2 (en) Compositions comprising peptide WKDEAGKPLVK
BR112015001451B1 (pt) Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
JP5883863B2 (ja) プロテアーゼ活性化受容体の調節剤
JP7780811B2 (ja) Ｄａｐｋ１リン酸化基質の人工低分子干渉ペプチド及びその製薬上の用途
JP5700641B2 (ja) メタスチン誘導体およびその用途
JPH10502091A (ja) ＰＴＨまたはＰＴＨｒＰアンタゴニスト
CN102088992A (zh) 肽基二酰基甘油酯
HK40074479A (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
CN101951942B (zh) Mntf肽组合物及使用方法
JP6710416B2 (ja) 炎症性皮膚疾患の予防又は治療剤
JP2014524923A (ja) プロテアーゼ活性化受容体の調節剤
US10059743B2 (en) Peptide derivative for regulating thymic stromal lymphoid protein-mediated signaling and pharmaceutical composition for preventing and treating allergy and asthma diseases comprising same
AU2003231331A1 (en) Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same
US20210113652A1 (en) Maspin-based inhibition of osteoclast activity and promotion of bone formation
CN103209989B (zh) 环肽化合物或其药用盐及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant